期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 58, 期 19, 页码 6285-6289出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201900788
关键词
CRISPR-Cas9; genome editing; photocaging; transcription; trimethoprim
资金
- Burroughs Wellcome Fund (Career Award at the Scientific Interface)
- DARPA [N66001-17-2-4055]
- NIH [R21AI126239]
- Army Research Office Award [W911NF1610586]
- U.S. Department of Defense (DOD) [W911NF1610586] Funding Source: U.S. Department of Defense (DOD)
Several genome engineering applications of CRISPR-Cas9, an RNA-guided DNA endonuclease, require precision control of Cas9 activity over dosage, timing, and targeted site in an organism. While some control of Cas9 activity over dose and time have been achieved using small molecules, and spatial control using light, no singular system with control over all the three attributes exists. Furthermore, the reported small-molecule systems lack wide dynamic range, have background activity in the absence of the small-molecule controller, and are not biologically inert, while the optogenetic systems require prolonged exposure to high-intensity light. We previously reported a small-molecule-controlled Cas9 system with some dosage and temporal control. By photocaging this Cas9 activator to render it biologically inert and photoactivatable, and employing next-generation protein engineering approaches, we have built a system with a wide dynamic range, low background, and fast photoactivation using a low-intensity light while rendering the small-molecule activator biologically inert. We anticipate these precision controls will propel the development of practical applications of Cas9.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据